Overnight Millionaires or a Decade-Long Marathon? Deconstructing the Drug Patent Approval Effect on Stocks
Introduction: The Allure of the Biotech Lottery: Beyond the Hype Scan the financial headlines on any given day, and you’re […]
Mine the Graveyard: How Abandoned Drug Patents and Unclaimed Chemical Space Become Your Competitor’s Next Blockbuster
In the spring of 2014, a small biotech called Idenix Pharmaceuticals held patents covering certain nucleotide analogue structures with antiviral
Drug Patent Cliffs Tell You Who Needs a New Tablet Press
How Drug Patent LOE forecasting gives equipment suppliers a 24-month head start on their competitors Every year, branded pharmaceutical companies
Drug Patent Cliffs Tell You Who Needs a New Tablet Press Read Post »
Know Your Clock: The Complete Latin American Guide to Drug Patent Duration
The Question Nobody Answers Clearly Ask a pharmaceutical executive how long a drug patent lasts in Latin America and you
Know Your Clock: The Complete Latin American Guide to Drug Patent Duration Read Post »
Drug Patents Don’t Last as Long as You Think
The Number Everyone Quotes Is Wrong Twenty years. Ask anyone in the pharmaceutical industry how long a drug patent lasts,
Drug Patents Don’t Last as Long as You Think Read Post »
Sell Granulation Systems Before the Drug Patent Expires: How Biopharma Equipment Suppliers Can Turn Drug LOE Timelines Into a Predictable Sales Pipeline
There is a predictable moment in generic drug manufacturing when a company’s capital expenditure committee approves a granulation line that
Turn Drug Patent Cliffs Into Contracts: How Formulation Vendors Win Pediatric Business with LOE Intelligence
The business development playbook at most contract development and manufacturing organizations (CDMOs) and formulation vendors follows a predictable arc: attend
Sell the Drug Patent Cliff Before They Fall Off It: How Biopharma Commercial and Market Access Vendors Can Build Class-Specific LOE Intelligence Reports Into a Scalable Revenue Line
There is a moment inside every biopharma brand team, usually around 36 months before patent expiration, when the commercial organization
FDA Orange Book Monitoring: The Subscription Your Biopharma Clients Will Never Cancel
Every quarter, brand-name pharmaceutical manufacturers risk losing billions in revenue because a generic competitor files an Abbreviated New Drug Application
FDA Orange Book Monitoring: The Subscription Your Biopharma Clients Will Never Cancel Read Post »
